218 related articles for article (PubMed ID: 16459166)
1. The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.
Baker AF; Dragovich T; Tate WR; Ramanathan RK; Roe D; Hsu CH; Kirkpatrick DL; Powis G
J Lab Clin Med; 2006 Feb; 147(2):83-90. PubMed ID: 16459166
[TBL] [Abstract][Full Text] [Related]
2. The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging.
Jordan BF; Runquist M; Raghunand N; Gillies RJ; Tate WR; Powis G; Baker AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):529-36. PubMed ID: 15701837
[TBL] [Abstract][Full Text] [Related]
3. A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers.
Baker AF; Adab KN; Raghunand N; Chow H; Stratton SP; Squire SW; Boice M; Pestano LA; Kirkpatrick DL; Dragovich T
Invest New Drugs; 2013 Jun; 31(3):631-641. PubMed ID: 22711542
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy.
Ramanathan RK; Stephenson JJ; Weiss GJ; Pestano LA; Lowe A; Hiscox A; Leos RA; Martin JC; Kirkpatrick L; Richards DA
Invest New Drugs; 2012 Aug; 30(4):1591-6. PubMed ID: 21863237
[TBL] [Abstract][Full Text] [Related]
5. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation.
Welsh SJ; Williams RR; Birmingham A; Newman DJ; Kirkpatrick DL; Powis G
Mol Cancer Ther; 2003 Mar; 2(3):235-43. PubMed ID: 12657718
[TBL] [Abstract][Full Text] [Related]
6. Effects of the thioredoxin-1 inhibitor PX-12 on blood-brain barrier permeability in the early stage of focal cerebral ischemia.
Chi OZ; Barsoum S; Grayson J; Liu X; Weiss HR
Pharmacology; 2013; 92(3-4):175-81. PubMed ID: 24060905
[TBL] [Abstract][Full Text] [Related]
7. Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase.
Kim YH; Coon A; Baker AF; Powis G
Cancer Chemother Pharmacol; 2011 Aug; 68(2):405-13. PubMed ID: 21069338
[TBL] [Abstract][Full Text] [Related]
8. Thioredoxin-1 inhibitor, 1-methylpropyl 2-imidazolyl disulfide, inhibits the growth, migration and invasion of colorectal cancer cell lines.
Wang F; Lin F; Zhang P; Ni W; Bi L; Wu J; Jiang L
Oncol Rep; 2015 Feb; 33(2):967-73. PubMed ID: 25483731
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.
Ramanathan RK; Abbruzzese J; Dragovich T; Kirkpatrick L; Guillen JM; Baker AF; Pestano LA; Green S; Von Hoff DD
Cancer Chemother Pharmacol; 2011 Mar; 67(3):503-9. PubMed ID: 20461382
[TBL] [Abstract][Full Text] [Related]
10. Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxide.
Tan Y; Bi L; Zhang P; Wang F; Lin F; Ni W; Wu J; Jiang L
Int J Clin Exp Pathol; 2014; 7(8):4765-73. PubMed ID: 25197347
[TBL] [Abstract][Full Text] [Related]
11. A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors.
Ramanathan RK; Kirkpatrick DL; Belani CP; Friedland D; Green SB; Chow HH; Cordova CA; Stratton SP; Sharlow ER; Baker A; Dragovich T
Clin Cancer Res; 2007 Apr; 13(7):2109-14. PubMed ID: 17404093
[TBL] [Abstract][Full Text] [Related]
12. The Thioredoxin-1 Inhibitor, PX-12, Suppresses Local Osteosarcoma Progression.
Kinoshita H; Shimozato O; Ishii T; Kamoda H; Hagiwara Y; Ohtori S; Yonemoto T
Anticancer Res; 2021 Dec; 41(12):6013-6021. PubMed ID: 34848455
[TBL] [Abstract][Full Text] [Related]
13. Parallel syntheses of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents.
Kirkpatrick DL; Watson S; Kunkel M; Fletcher S; Ulhaq S; Powis G
Anticancer Drug Des; 1999 Oct; 14(5):421-32. PubMed ID: 10766297
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides.
Kirkpatrick DL; Kuperus M; Dowdeswell M; Potier N; Donald LJ; Kunkel M; Berggren M; Angulo M; Powis G
Biochem Pharmacol; 1998 Apr; 55(7):987-94. PubMed ID: 9605422
[TBL] [Abstract][Full Text] [Related]
15. Thioredoxin Confers Intrinsic Resistance to Cytostatic Drugs in Human Glioma Cells.
Haas B; Schütte L; Wos-Maganga M; Weickhardt S; Timmer M; Eckstein N
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30248944
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of disulfides as anticancer agents with thioredoxin inhibition.
Wei X; Zhong M; Wang S; Li L; Song ZL; Zhang J; Xu J; Fang J
Bioorg Chem; 2021 May; 110():104814. PubMed ID: 33756234
[TBL] [Abstract][Full Text] [Related]
17. Targeting Thioredoxin System with an Organosulfur Compound, Diallyl Trisulfide (DATS), Attenuates Progression and Metastasis of Triple-Negative Breast Cancer (TNBC).
Liu Y; Zhao Y; Wei Z; Tao L; Sheng X; Wang S; Chen J; Ruan J; Liu Z; Cao Y; Shan Y; Wang A; Chen W; Lu Y
Cell Physiol Biochem; 2018; 50(5):1945-1963. PubMed ID: 30396169
[TBL] [Abstract][Full Text] [Related]
18. PX-12 inhibits the growth of A549 lung cancer cells via G2/M phase arrest and ROS-dependent apoptosis.
You BR; Shin HR; Park WH
Int J Oncol; 2014 Jan; 44(1):301-8. PubMed ID: 24172913
[TBL] [Abstract][Full Text] [Related]
19. Thioredoxin system modulation by plant and fungal secondary metabolites.
Dal Piaz F; Braca A; Belisario MA; De Tommasi N
Curr Med Chem; 2010; 17(5):479-94. PubMed ID: 19941471
[TBL] [Abstract][Full Text] [Related]
20. Experimental study on thioredoxin redox inhibitor 1-methylpropyl 2-imidazolyl disulfide promoting apoptosis of multiple myeloma cells in vitro and in vivo.
Lin QD; Liu LN; Liu XY; Yan Y; Fang BJ; Zhang YL; Zhou J; Li YF; Zuo WL; Song YP
Eur Rev Med Pharmacol Sci; 2022 Feb; 26(4):1283-1292. PubMed ID: 35253185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
